Arcus Biosciences and Gilead Sciences have reported promising Phase III results from their ARC-10 study of domvanalimab and ...

The safety and overall survival seen in the ARC-10 trial lends further support to the firm's strategy of pairing domvanalimab and zimberelimab with chemo in STAR-121.

The role of TIGIT as a target for immuno-oncology therapies has been called into question again after it was revealed that Novartis handed back rights to a drug partnered with China’s BeiGene.

The finance round was led by OrbiMed and comes almost exactly two years after Mereo decided to pull a US IPO, blaming challenging market conditions. In the phase 1b combination study, a total of ...

Ar­cus Bio­sciences un­veiled da­ta from a ter­mi­nat­ed late-stage study of its TIG­IT and PD-1 drug com­bo that it says sup­ports its de­ci­sion to take the … ...

AstraZeneca is under scrutiny in China — as its top executive there and other personnel are being investigated by authorities ...

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination ...

In a report released yesterday, Jason Zemansky from Bank of America Securities maintained a Hold rating on Arcus Biosciences (RCUS – ...

Domvanalimab (dom). The company’s most advanced asset is dom, an Fc-silent anti-TIGIT monoclonal antibody that is undergoing evaluation in three registrational trials for the treatment of ...

Arcus Biosciences Inc (RCUS) reports robust financial health and strategic advancements in late-stage trials, despite facing ...

This study is a randomized, open-label, three-arm study evaluating domvanalimab, an Fc-silent anti-TIGIT monoclonal antibody, plus zimberelimab, an anti-PD-1 monoclonal antibody, versus ...

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today ...